FDA Must Clarify Off-Label Marketing Rules, House Committee Says
This article was originally published in The Gray Sheet
Executive Summary
The letter, which follows several legal rulings that FDA’s policy impedes manufacturers’ free-speech rights, includes a draft amendment that would greatly broaden the range of permissible venues for truthful off-label speech.